Literature DB >> 2677936

Maternal-placental-fetal unit: unique problems of pharmacologic study.

R M Ward1.   

Abstract

Fetal exposure to different drugs has increased, but few prospective, controlled, blinded trials have been conducted of adverse fetal effects following fetal drug exposure. The quantitative exposure of the fetus to drugs varies during pregnancy with changes in the MPFU. Prospective, controlled, blinded studies of adverse fetal effects of drugs are very difficult; investigators therefore have used alternative study designs that make the conclusions more tentative. Such studies may be limited by accuracy of recall of drug intake and its timing, oversimplification of complex drug exposure, separating the effects of drugs from that of the underlying disease, and a lack of correlation between human and animal effects of fetal drug exposure. Intentional drug treatment of the fetus has begun but should proceed from thorough laboratory study to clinical applications, not the reverse.

Entities:  

Mesh:

Year:  1989        PMID: 2677936     DOI: 10.1016/s0031-3955(16)36758-x

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  5 in total

Review 1.  Pharmacological treatment of the fetus. Clinical pharmacokinetic considerations.

Authors:  R M Ward
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

2.  Transplacental transfer of cefuroxime in uncomplicated pregnancies and those complicated by hydrops or changes in amniotic fluid volume.

Authors:  D E Holt; N M Fisk; J A Spencer; J de Louvois; R Hurley; D Harvey
Journal:  Arch Dis Child       Date:  1993-01       Impact factor: 3.791

3.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.

Authors:  Ravi Thadhani; Henning Hagmann; Wiebke Schaarschmidt; Bernhard Roth; Tuelay Cingoez; S Ananth Karumanchi; Julia Wenger; Kathryn J Lucchesi; Hector Tamez; Tom Lindner; Alexander Fridman; Ulrich Thome; Angela Kribs; Marco Danner; Stefanie Hamacher; Peter Mallmann; Holger Stepan; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

4.  Pharmacokinetics of intravenous acyclovir, zidovudine, and acyclovir-zidovudine in pregnant rats.

Authors:  Stacy D Brown; Michael G Bartlett; Catherine A White
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Medical databases in studies of drug teratogenicity: methodological issues.

Authors:  Vera Ehrenstein; Henrik T Sørensen; Leiv S Bakketeig; Lars Pedersen
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.